Teva Pharmaceutical Industries Limited (TEVA)
NYSE: TEVA · Real-Time Price · USD
34.31
-0.06 (-0.17%)
At close: Feb 11, 2026, 4:00 PM EST
34.74
+0.43 (1.25%)
After-hours: Feb 11, 2026, 7:59 PM EST
Teva Pharmaceutical Revenue
In the year 2025, Teva Pharmaceutical had annual revenue of $17.26B with 4.32% growth. Teva Pharmaceutical had revenue of $4.71B in the quarter ending December 31, 2025, with 11.40% growth.
Revenue (ttm)
$17.26B
Revenue Growth
+4.32%
P/S Ratio
2.28
Revenue / Employee
$508,336
Employees
33,950
Market Cap
39.96B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 17.26B | 714.00M | 4.32% |
| Dec 31, 2024 | 16.54B | 698.00M | 4.40% |
| Dec 31, 2023 | 15.85B | 921.00M | 6.17% |
| Dec 31, 2022 | 14.93B | -953.00M | -6.00% |
| Dec 31, 2021 | 15.88B | -781.00M | -4.69% |
| Dec 31, 2020 | 16.66B | -228.00M | -1.35% |
| Dec 31, 2019 | 16.89B | -1.38B | -7.57% |
| Dec 31, 2018 | 18.27B | -3.58B | -16.39% |
| Dec 31, 2017 | 21.85B | -50.00M | -0.23% |
| Dec 31, 2016 | 21.90B | 2.25B | 11.45% |
| Dec 31, 2015 | 19.65B | -620.00M | -3.06% |
| Dec 31, 2014 | 20.27B | -42.00M | -0.21% |
| Dec 31, 2013 | 20.31B | -3.00M | -0.01% |
| Dec 31, 2012 | 20.32B | 2.01B | 10.95% |
| Dec 31, 2011 | 18.31B | 2.19B | 13.59% |
| Dec 31, 2010 | 16.12B | 2.22B | 15.99% |
| Dec 31, 2009 | 13.90B | 2.81B | 25.39% |
| Dec 31, 2008 | 11.09B | 1.68B | 17.83% |
| Dec 31, 2007 | 9.41B | 1.00B | 11.89% |
| Dec 31, 2006 | 8.41B | 3.16B | 60.15% |
| Dec 31, 2005 | 5.25B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Takeda Pharmaceutical Company | 28.48B |
| Haleon | 15.10B |
| Viatris | 14.12B |
| Zoetis | 9.40B |
| Elanco Animal Health | 4.59B |
| Dr. Reddy's Laboratories | 3.85B |
| United Therapeutics | 3.13B |
| Amneal Pharmaceuticals | 2.93B |
TEVA News
- 14 days ago - Teva Pharmaceutical Industries Limited (TEVA) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 14 days ago - Teva's Flagship Drugs Hit $1 Billion Milestone, Raises Confidence In 2026 Outlook - Benzinga
- 14 days ago - Teva Pharmaceutical profit, revenue rise in fourth quarter - Reuters
- 14 days ago - Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential - GlobeNewsWire
- 15 days ago - Will Forte Teams Up with Teva to Get Real About Huntington's Disease with ‘Honestly HD' - GlobeNewsWire
- 4 weeks ago - AJOVY® (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and Adolescents with Episodic Migraine Compared to Placebo in the SPACE Trial; Results Published in New England Journal of Medicine - GlobeNewsWire
- 4 weeks ago - Teva Is No Longer A Turnaround Story, It's A Growth One - Seeking Alpha
- 4 weeks ago - Teva Pharmaceutical Industries Limited (TEVA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha